AU6605196A - Method of treating hepatitis delta virus infection - Google Patents

Method of treating hepatitis delta virus infection

Info

Publication number
AU6605196A
AU6605196A AU66051/96A AU6605196A AU6605196A AU 6605196 A AU6605196 A AU 6605196A AU 66051/96 A AU66051/96 A AU 66051/96A AU 6605196 A AU6605196 A AU 6605196A AU 6605196 A AU6605196 A AU 6605196A
Authority
AU
Australia
Prior art keywords
virus infection
treating hepatitis
hepatitis delta
delta virus
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU66051/96A
Inventor
Patrick J Casey
James C. Otto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of AU6605196A publication Critical patent/AU6605196A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
AU66051/96A 1996-02-29 1996-07-31 Method of treating hepatitis delta virus infection Abandoned AU6605196A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1248696P 1996-02-29 1996-02-29
US60012486 1996-02-29
PCT/US1996/012501 WO1997031641A1 (en) 1996-02-29 1996-07-31 Method of treating hepatitis delta virus infection

Publications (1)

Publication Number Publication Date
AU6605196A true AU6605196A (en) 1997-09-16

Family

ID=21755201

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66051/96A Abandoned AU6605196A (en) 1996-02-29 1996-07-31 Method of treating hepatitis delta virus infection

Country Status (2)

Country Link
AU (1) AU6605196A (en)
WO (1) WO1997031641A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249564A1 (en) 2000-03-29 2001-10-08 Cornell Research Foundation Inc. Method of treating hepatitis delta viral infection
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
WO2011088126A2 (en) * 2010-01-13 2011-07-21 Eiger Biopharmaceuticals, Inc. Treatment of viral infection with prenyltransferase inhibitors
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JP2017536403A (en) * 2014-12-04 2017-12-07 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Treatment of hepatitis delta virus infection
JP2018517673A (en) 2015-04-21 2018-07-05 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． A pharmaceutical composition comprising lonafamib and ritonavir

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420245A (en) * 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
US5503973A (en) * 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
IL111258A0 (en) * 1993-10-15 1994-12-29 Schering Corp Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases

Also Published As

Publication number Publication date
WO1997031641A1 (en) 1997-09-04

Similar Documents

Publication Publication Date Title
AU1566595A (en) Method and reagent for inhibiting hepatitis c virus replication
AU6479696A (en) Antisense inhibition of hepatitis b virus replication
AU4803196A (en) Recombinant DNA virus and method for preparation thereof
AU4813197A (en) Compositions and methods for treating viral infections
AU2296995A (en) Composition and method for treatment of cmv infection
AU2158000A (en) Treatment of hepatitis c virus infections with interleukin-10
AU1733697A (en) Method of purifying and removing viruses
AU2002346686A1 (en) Compositions and method for treating hepatitis virus infection
AU7326494A (en) Nucleotide sequences and process for amplifying and detection of hepatitis b virus
EP0933803A4 (en) Method of plasma treatment
EP0608212A4 (en) Method of treating viral infection.
AU6703394A (en) Method of treating depression using neurotrophins
AU6605196A (en) Method of treating hepatitis delta virus infection
AU4602897A (en) Method for treatment of immunodeficiency virus infection
EP1202750A4 (en) Method of treating hiv infection and related secondary infections thereof
ZA972722B (en) Method for prevention and treatment of viral infectious diseases.
AU4132096A (en) Compositions and methods for interfering with hepatitis b virus infection
AU5085693A (en) Method of treating epstein-barr virus infection
AU1808501A (en) Tricyclic compounds and method of treating herpes virus
AU6378598A (en) Method for inhibition of virus replication
AU6559194A (en) Method of treating hepatitis b infection
AU3530395A (en) Treatment of viral infections
AU2028297A (en) Method for predicting the outcome of hepatitis b infection
AU4027097A (en) Method of treatment
AU8704998A (en) A pharmaceutical composition for treating hepatitis B virus (HBV) infection